5 Top Losers In Healthcare Sector (VRNA, NBY, STRO...)

pharmadown jan14

The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

1. Verona Pharma plc (VRNA)

Lost 30.30% to close Monday's (Jan.14) trading at $6.97.

News: The Company's 3-day phase II trial evaluating nebulized Ensifentrine (RPL554) on top of dual bronchodilator therapy for chronic obstructive pulmonary disease maintenance treatment did not meet the primary endpoint of peak forced expiratory volume in one second ("FEV1").

A phase II trial evaluating a dry powder inhaler formulation of Ensifentrine for the maintenance treatment of COPD is underway.

2. Novan Inc. (NOVN)

Lost 18.24% to close Monday's trading at $1.30.

News: No news

Clinical Trials & Near-term Catalyst:

The Company's lead asset is SB206, a phase III-ready compound for the treatment of molluscum contagiosum.

A phase III program of SB206 for molluscum contagiosum is expected to begin in the first half of 2019 - with top-line results possible by the end of 2019 or early in 2020.

Molluscum contagiosum is a common skin disease caused by a virus and is characterized by pink or flesh-colored bumps on the skin (Source: American Academy of Dermatology).

3. Proteostasis Therapeutics Inc. (PTI)

Lost 15.01% to close Monday's trading at $3.34.

News: No news

Clinical Trials & Near-term Catalysts:

A phase I study of the Company's proprietary combination therapy triplet (PTI-808, PTI-801, and PTI-428) in cystic fibrosis is ongoing.

Studies exploring a proprietary doublet (PTI-808 and PTI-801), and separate studies of PTI-801 and PTI-428 with background SYMDEKO therapy, in cystic fibrosis subjects, are underway.

Data read-out from the studies is expected in the first quarter of 2019.

4. NovaBay Pharmaceuticals Inc. (NBY)

The Company is focused on commercializing prescription Avenova for the domestic eye care market.

Avenova is designed for removal of the microorganisms and debris that contribute to conditions such as meibomian gland dysfunction, dry eye, and blepharitis.

Lost 13.33% to close Monday's trading at $0.91.

News: No news

Recent event:

On January 7, the Company announced preliminary 2018 net sales and provided 2019 net sales guidance.

For 2018, the net sales are expected to be $12.6 million to $12.7 million. Net sales for 2017 were $18.2 million.

Looking ahead to 2019, net sales are anticipated to be approximately $16.0 million to $16.5 million.

5. Sutro Biopharma Inc. (STRO)

Lost 11.18% to close Monday's trading at $9.61.

News: No news

Recent event:

On September 27, 2018, the Company went public on The Nasdaq Global Market offering its shares at a price of $15.00 each.

Clinical Trials & Near-term Catalysts:

-- A phase I trial of STRO-002 in patients with Ovarian and Endometrial cancers is expected to begin in early 2019.
-- A phase I clinical trial of STRO-001 enrolling separate dose escalation cohorts for myeloma and B-cell lymphoma is underway.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT